Entrada Q1 net income $23.5M; Vertex $75M milestone; DMD Phase 1 final cohort dosed; cash runway to Q2 2026

Entrada Therapeutics, Inc.

2024-Q1 EPS reported $0.68 revenue$59,120,000

Net income $23.5M vs loss ($6.7M) Q1 2023; collaboration revenue $59.1M (up from $25.3M) on Vertex $75M milestone.
Initiated dosing of 4th & final cohort of Phase 1 trial for ENTR-601-44 in DMD exon 44; data readout expected Oct 2024.
Cash, cash equivalents & marketable securities $327.4M as of Mar 31, 2024; cash runway expected through Q2 2026.
On track to submit regulatory apps in Q4 2024 for Phase 2 studies of ENTR-601-44 (DMD exon 44) and ENTR-601-45 (exon 45).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Entrada Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $59.1 million, net income $23.5 million.

Period: first quarter ended March 31, 2024
Revenue: $59.1 million
Net income: $23.5 million
Result: reported results

Exact text from the filing

of EEV therapeutic candidates targeting DMD and advance EEV-therapeutic candidates in indications beyond neuromuscular disease. Collaboration Revenue: Collaboration revenue was $59.1 million for the first quarter of 2024, compared to $25.3 million for the same period in 2023. The increase was primarily a result of the clinical advancement milestone achieved in the

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.